Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from ...

Leerink downgraded Elevation Oncology (ELEV) to Market Perform from Outperform with a price target of $1, down from $9, after the company ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of ...

Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research ...

Analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Shattuck Labs in a report released on Monday ...

Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...

Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting ...

today announced its participation in a fireside chat at the Leerink Healthcare Conference on Wednesday, March 12, 2025 at 10:00 a.m. ET. A live webcast will be available on the Investors & Media ...

will participate in a fireside chat at Leerink's 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 10:40 am ET. A live webcast will be available on the Alumis website in the ...

SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the ...

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph ...